Charles River (CRL) director James C. Foster exercises options and sells 28,733 shares
Rhea-AI Filing Summary
Charles River Laboratories International director James C. Foster exercised stock options for 28,733 shares of common stock at an exercise price of $179.66 per share on August 10, 2026 and immediately sold 28,733 shares at $275.00 per share. The options, originally exercisable from May 29, 2021 and expiring May 29, 2030, now show 0 derivative shares remaining from this grant. The exercise and sale occurred pursuant to a Rule 10b5-1 Trading Plan initially adopted on March 6, 2026. Following these transactions, Foster is reported with indirect holdings of common stock through various trusts and GRATs, including 5,423 shares in a 2024 GRAT, 10,780 shares in a 2025 GRAT, and 20,000 shares in a 2026 GRAT.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Exercise and Sale: 28,733 shares ($2.74M approx. pre-tax spread)
Exercise and Sale
8 txns
Insider
FOSTER JAMES C
Role
Director
Sold
28,733 shs ($7.90M)
Approx. gross sale proceeds
$7.90M
Approx. exercise cost
$5.16M
Approx. pre-tax spread
$2.74M
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Options (Right to Buy) | 28,733 | $0.00 | $0.00 |
| Exercise | Common Stock | 28,733 | $179.66 | $5.16M |
| Sale | Common Stock F1 | 28,733 | $275.00 | $7.90M |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Stock Options (Right to Buy) — 0 shares (Direct);
Common Stock — 31,596 shares (Direct);
Common Stock — 5,423 shares (Indirect, 2024 GRAT);
Common Stock — 10,780 shares (Indirect, 2025 GRAT);
Common Stock — 20,000 shares (Indirect, 2026 GRAT);
Common Stock — 155,611 shares (Indirect, By Trust);
Common Stock — 10,000 shares (Indirect, By Trust Held By Spouse)
Footnotes (1)
- F1. This exercise and sale occurred pursuant to a Rule 10b5-1 Trading Plan that was initially adopted on March 6, 2026.
Key Figures
Options Exercised: 28,733 shares
Exercise Price: $179.66 per share
Sale Price: $275.00 per share
+4 more
7 metrics
Options Exercised
28,733 shares
Stock options (right to buy) exercised on August 10, 2026
Exercise Price
$179.66 per share
Exercise price of stock options converted into common stock
Sale Price
$275.00 per share
Price for sale of 28,733 common shares on August 10, 2026
Shares Sold
28,733 shares
Common stock sold in non-derivative transaction coded S
2024 GRAT Holdings
5,423 shares
Indirect common stock holdings through 2024 GRAT after transactions
2025 GRAT Holdings
10,780 shares
Indirect common stock holdings through 2025 GRAT after transactions
2026 GRAT Holdings
20,000 shares
Indirect common stock holdings through 2026 GRAT after transactions
Key Terms
Rule 10b5-1 Trading Plan, Stock Options (Right to Buy), derivative security, GRAT, +1 more
5 terms
Rule 10b5-1 Trading Plan regulatory
"This exercise and sale occurred pursuant to a Rule 10b5-1 Trading Plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
Stock Options (Right to Buy) financial
"security_title: Stock Options (Right to Buy)"
derivative security financial
"transaction_code_description: Exercise or conversion of derivative security"
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
GRAT financial
"nature_of_ownership: 2024 GRAT"
By Trust Held By Spouse financial
"nature_of_ownership: By Trust Held By Spouse"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transaction did CRL director James C. Foster report on August 10, 2026?
James C. Foster reported exercising stock options for 28,733 shares of Charles River Laboratories common stock at $179.66 per share and selling 28,733 shares at $275.00 per share, all on August 10, 2026, as disclosed in the Form 4.
Was the August 10, 2026 CRL insider sale by James C. Foster under a Rule 10b5-1 plan?
Yes. The exercise and sale of 28,733 CRL shares by James C. Foster occurred under a Rule 10b5-1 Trading Plan that was initially adopted on March 6, 2026, indicating the trades were pre-arranged rather than discretionary.
What stock option terms applied to James C. Foster’s CRL option exercise reported in this Form 4?
Foster exercised stock options covering 28,733 shares of Charles River Laboratories common stock at an exercise price of $179.66 per share. The option grant became exercisable on May 29, 2021 and carried an expiration date of May 29, 2030 before this full exercise.
At what price did James C. Foster sell CRL common stock on August 10, 2026?
He sold 28,733 shares of Charles River Laboratories common stock at a reported price of $275.00 per share on August 10, 2026. The transaction is coded as a sale (code S) in the Form 4’s non-derivative transaction table.
How many CRL stock options remained from the exercised grant after James C. Foster’s transaction?
From this particular option grant, the Form 4 reports 0 derivative shares remaining following the August 10, 2026 exercise of 28,733 options, indicating that this specific grant of stock options was fully exercised in the reported transaction.